Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insmed iPlex Growth Agent “Approvable” Letter Leaves Orphan Status Issue Open

This article was originally published in The Pink Sheet Daily

Executive Summary

Exclusivity discussions with Office of Orphan Products Development are ongoing, CEO Geoffrey Allan says Sept. 28; letter requests chemistry, manufacturing and controls data.

You may also be interested in...



Insmed’s iPlex Gets Updated User Fee Date Of Dec. 12

Insmed's NDA for the growth therapy iPlex (mecasermin rinfibate) has an updated user fee date of Dec. 12, the firm announced Oct. 25

Insmed’s iPlex Gets Updated User Fee Date Of Dec. 12

Insmed's NDA for the growth therapy iPlex (mecasermin rinfibate) has an updated user fee date of Dec. 12, the firm announced Oct. 25

Tercica’s Growth Treatment Increlex Clears FDA With Orphan Drug Exclusivity

The company plans to launch the extreme short stature therapy in January with a 30-member sales force.

Related Content

Topics

UsernamePublicRestriction

Register

PS062961

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel